Welcome to our dedicated page for Y-Mabs Therapeutics news (Ticker: YMAB), a resource for investors and traders seeking the latest updates and insights on Y-Mabs Therapeutics stock.
Y-mAbs Therapeutics, Inc. (YMAB) was a commercial-stage biopharmaceutical company focused on antibody-based and radiopharmaceutical cancer therapies. Company news centered on DANYELZA® (naxitamab-gqgk), an anti-GD2 therapy for relapsed or refractory high-risk neuroblastoma, and on clinical development of the SADA Pretargeted Radioimmunotherapy platform, including GD2-SADA and CD38-SADA programs.
Recurring updates also covered R&D presentations, NCCN guideline references, quarterly operating and financial results, material agreements, capital-structure disclosures and governance matters. Later corporate-status news covered the completed merger, Nasdaq listing changes and the company’s transition out of public-company reporting.
Y-mAbs Therapeutics (NASDAQ: YMAB) presented preclinical data and trial progress for its CD38-SADA platform at the 2024 ASH Annual Meeting. The preclinical data demonstrated selective binding and anti-tumor efficacy of CD38-SADA when used with Lutetium 177-DOTA in treating Non-Hodgkin Lymphoma (NHL).
The company also presented details of its ongoing Phase 1 Trial 1201, evaluating CD38-SADA PRIT with Lu177-DOTA in adults with relapsed or refractory NHL. The trial consists of two parts: Part A focuses on dose escalation of CD38-SADA protein, while Part B aims to establish the optimal therapeutic dose of Lu177-DOTA. Both parts follow a 3+3 trial design with 4 planned dose levels.
Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company specializing in radioimmunotherapy and antibody-based cancer treatments, has announced its participation in Citi's 2024 Global Healthcare Conference. The company's management team will conduct one-on-one meetings at the conference on December 4, 2024 in Miami, FL. Interested parties can schedule meetings through their Citi representative or by contacting cdu@ymabs.com.
Y-mAbs Therapeutics reported Q3 2024 financial results with total DANYELZA net product revenues of $18.5 million, marking a 10% decline from Q3 2023. The company entered into an exclusive license agreement with Nobelpharma for DANYELZA in Japan, securing a $2.0 million upfront payment. Key developments include the extension of DANYELZA's U.S. patent through February 2034 and market expansion into Turkey. Net loss for Q3 2024 was $7.0 million ($0.16 per share), compared to $7.7 million in Q3 2023. The company maintains its 2024 guidance with expected total net revenues between $87-95 million and cash position supporting operations into 2027.
Y-mAbs Therapeutics (NASDAQ: YMAB) and Nobelpharma have signed an exclusive license and distribution agreement for DANYELZA® in Japan. The agreement covers the development and commercialization of DANYELZA for treating relapsed/refractory high-risk neuroblastoma and potentially relapsed osteosarcoma. Y-mAbs will receive a $2.0 million upfront payment and could earn up to $31.0 million in milestone payments, plus profit sharing on commercial sales. Nobelpharma will handle regulatory submissions, marketing, sales, and distribution in Japan.
Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on radioimmunotherapy and antibody-based cancer treatments, has scheduled its third quarter 2024 financial results announcement. The company will release results before market open on November 8, 2024, followed by a conference call and webcast at 8:00 a.m. ET. Domestic investors can dial (877) 407-0792, while international investors can use (201) 689-8263 to participate.
Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company specializing in novel radioimmunotherapy and antibody-based therapeutic products for cancer treatment, has announced its participation in two upcoming investor conferences in October 2024:
1. Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit:
- Date: Tuesday, October 8, 2024
- Time: 9:30 a.m. ET
- Location: New York, NY
- Panel: "The Next Wave of TRTs – Targets, Targeting Technologies and Isotopes"
2. BMO Oncology Summit:
- Date: Tuesday, October 8, 2024
- Time: 3:00 p.m. ET
- Location: New York, NY
- Fireside chat: "Shifting the Antibody Paradigm"
These conferences provide Y-mAbs with opportunities to showcase its developments in cancer therapeutics and engage with investors.
Y-mAbs Therapeutics (Nasdaq: YMAB) presented new clinical and preclinical data on naxitamab and GD2-SADA for neuroblastoma treatment at the AACR Special Conference. Key findings include:
1. Naxitamab with GM-CSF achieved a 63% disease control rate in refractory/relapsed high-risk neuroblastoma patients.
2. GD2-SADA demonstrated high-affinity binding to Tb-DOTA, supporting its potential in pre-targeted radiotherapy (PRIT).
3. Ongoing clinical trials: Trial 201 for naxitamab, Trial 1001 for GD2-SADA PRIT in adolescents and adults, and planned Trial 1002 for pediatric patients.
These results highlight Y-mAbs' progress in developing innovative treatments for high-risk neuroblastoma, the most common extracranial solid tumor in children.
Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company specializing in novel radioimmunotherapy and antibody-based therapeutic products for cancer treatment, has announced its participation in two upcoming investor conferences. Michael Rossi, President and CEO, will represent the company at:
1. Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024, at 1:50 p.m. ET in New York, NY.
2. Cantor Global Healthcare Conference on September 17, 2024, at 3:40 p.m. ET in New York, NY.
Both events will feature fireside chats and investor 1x1 meetings. Live webcasts of the fireside chats and related materials will be available on Y-mAbs' investor relations website under the Presentations section, with archives accessible for at least 30 days.
Y-mAbs Therapeutics (YMAB) reported Q2 2024 financial results and corporate developments. Highlights include:
- DANYELZA net product revenues of $22.8 million, up 10% YoY
- Geographic expansion with new revenues from Brazil and Mexico
- Phase 1 GD2-SADA Trial Part A expected completion in Q4 2024
- Appointed new CFO and Chief Development Officer
- Cash and cash equivalents of $77.8 million as of June 30, 2024
- Updated Full Year 2024 Total Net Revenue guidance
The company reported a net loss of $9.2 million ($0.21 per share) for Q2 2024, compared to a $6.3 million loss ($0.14 per share) in Q2 2023. Management expects current cash to support operations into 2027.
Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company specializing in novel radioimmunotherapy and antibody-based cancer treatments, has announced its participation in two upcoming investor conferences in August 2024:
1. Wedbush PacGrow Healthcare Conference on August 13 in New York, NY, featuring investor 1x1 meetings.
2. Canaccord Genuity 44th Annual Growth Conference on August 14 in Boston, MA, including a fireside chat at 8:00 a.m. ET and investor 1x1 meetings.
A live webcast of Y-mAbs' fireside chat and related materials will be available on the company's investor relations website. The webcast will be archived for at least 30 days.